Artwork

Контент предоставлен Archive. Весь контент подкастов, включая выпуски, графику и описания подкастов, загружается и предоставляется непосредственно Archive или его партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Player FM - приложение для подкастов
Работайте офлайн с приложением Player FM !

Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation?

51:37
 
Поделиться
 

Архивные серии ("Канал не активен" status)

When? This feed was archived on October 21, 2023 05:48 (5M ago). Last successful fetch was on September 28, 2019 01:48 (4+ y ago)

Why? Канал не активен status. Нашим серверам не удалось получить доступ к каналу подкаста в течении длительного периода времени.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 151514513 series 1029942
Контент предоставлен Archive. Весь контент подкастов, включая выпуски, графику и описания подкастов, загружается и предоставляется непосредственно Archive или его партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
http://www.StockMarketFunding.com Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Wall St is hyping the suicidal results. We believe today's "pre market" manipulation in price action caused some large institutions to take a short position going into the move and the FDA Program Schedule Released at 8 AM today did not show any meaningful new data. Premarket high was $29.50 and now we're trading at $24.50 $5 dollars lower. The new breakthrough in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.
BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.
  continue reading

5 эпизода

Artwork
iconПоделиться
 

Архивные серии ("Канал не активен" status)

When? This feed was archived on October 21, 2023 05:48 (5M ago). Last successful fetch was on September 28, 2019 01:48 (4+ y ago)

Why? Канал не активен status. Нашим серверам не удалось получить доступ к каналу подкаста в течении длительного периода времени.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 151514513 series 1029942
Контент предоставлен Archive. Весь контент подкастов, включая выпуски, графику и описания подкастов, загружается и предоставляется непосредственно Archive или его партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
http://www.StockMarketFunding.com Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Wall St is hyping the suicidal results. We believe today's "pre market" manipulation in price action caused some large institutions to take a short position going into the move and the FDA Program Schedule Released at 8 AM today did not show any meaningful new data. Premarket high was $29.50 and now we're trading at $24.50 $5 dollars lower. The new breakthrough in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.
BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.
  continue reading

5 эпизода

Все серии

×
 
Loading …

Добро пожаловать в Player FM!

Player FM сканирует Интернет в поисках высококачественных подкастов, чтобы вы могли наслаждаться ими прямо сейчас. Это лучшее приложение для подкастов, которое работает на Android, iPhone и веб-странице. Зарегистрируйтесь, чтобы синхронизировать подписки на разных устройствах.

 

Краткое руководство